

IN THE CLAIMS:

Please amend Claim 1 as follows:

1 (Amended). A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue or the neuromuscular junction of said human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of said human, comprising the step of:

A2  
B  
B  
a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), ~~other agents containing soluble TNF receptors,~~ CDP571 (a humanized monoclonal anti-TNF-alpha antibody), ~~other monoclonal anti-TNF-alpha antibodies,~~ [TNF - alpha converting enzyme inhibitors] and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue or the neuromuscular junction of said human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of said human.

REMARKS

Applicant affirms its election of Claims 1 to 29, and applicant has cancelled non-elected Claims 30 to 99. Applicant is filing a divisional application for these Claims.

Applicant also has submitted a terminal disclaimer to overcome the double patenting rejection of Claims 1 to 29.